Epstein-Barr virus lytic switch protein BZLF1 (BZLF1)

The Epstein-Barr virus (EBV) lytic switch protein BZLF1, also known as ZEBRA or Zta, is a critical immediate-early protein that serves as the master regulator for the transition from latent to lytic infection [1, 6]. As a member of the basic leucine zipper (bZIP) family of transcription factors, BZLF1 binds to specific DNA sequences known as Z-responsive elements (ZREs) to activate the expression of early lytic genes and initiates viral DNA replication by binding to the lytic origin of replication (oriLyt) [2, 8]. Beyond its role in the viral life cycle, BZLF1 modulates the host environment by inhibiting antiviral cytokine signaling, such as TNF and IFN-gamma, and disrupting MHC-II-mediated antigen presentation, thereby facilitating immune evasion [1, 2, 11]. In the context of disease, BZLF1 is expressed in various EBV-associated malignancies, including nasopharyngeal carcinoma, Burkitt lymphoma, and post-transplant lymphoproliferative disorders (PTLD), where it may contribute to tumorigenesis and viral dissemination [1, 5, 9]. Therapeutically, BZLF1 is a primary target for "lytic induction therapy," a strategy that uses agents like histone deacetylase (HDAC) inhibitors (e.g., valproic acid) or DNA-damaging drugs (e.g., gemcitabine) to force the virus into the lytic cycle, rendering infected cells susceptible to antiviral drugs like ganciclovir or inducing direct viral-mediated lysis [7, 10]. Additionally, BZLF1 is being investigated as a candidate antigen for EBV vaccine development to enhance T-cell-mediated immunosurveillance and prevent EBV-associated diseases [1, 9].

Other names

ZEBRAZtaEB1Protein ZTrans-activator protein BZLF1bZIP transcription factor ZEBRA

Lytic induction therapy (activation of BZLF1 expression to trigger the viral lytic cycle, leading to cell death or increased susceptibility to antiviral agents) [7, 10]